PDF herunterladen
Semin Thromb Hemost 2001; 27(2): 107-114
DOI: 10.1055/s-2001-14068
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Intraplacental Coagulation in Intrauterine Growth Restriction: Cause or Result?

Motoi Sugimura, Ryouta Ohashi, Takao Kobayashi, Naohiro Kanayama
  • Department of Obstetrics and Gynecology, Hamamatsu University, School of Medicine, Hamamatsu, Japan
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2001 (online)

    Lizenzen und Reprints

ABSTRACT

Growth-restricted fetuses with complications of pregnancy exhibit significantly increased perinatal morbidity and mortality compared with normal growth fetuses. Coagulation-related lesions such as uteroplacental vessel thrombosis and perivillous coagulation in the placentas with intrauterine growth restriction (IUGR) are reported in complicated pregnancy, while fibrin depositions and intervillous thrombi are observed in half of the placentas of full-term uncomplicated pregnancy. These observations raise the question whether coagulation in the placental circulation is a cause for the development of IUGR. Recently published IUGR models in animals demonstrate that antiphospholipid antibodies and procoagulant platelet-derived phospholipids induce IUGR with histopathological changes of coagulation-related lesions in the placenta. These experiments suggest that enhanced coagulation in the placental circulation can induce IUGR and that hypercoagulable states remain one of the important factors in the development of IUGR.

KEYWORD

Intrauterine growth restriction - thrombosis - hypercoagulability - coagulation - placental circulation

REFERENCES

  • 1 Kramer M S, Olivier M, McLean F H, Willis D M, Usher R H. Impact of intrauterine growth retardation and body proportionality on fetal and neonatal outcome.  Pediatrics . 1990;  86 707-713
    PubMedGoogle Scholar
  • 2 Chard T, Yoong A, Macintosh M. The myth of fetal growth retardation at term.  Br J Obstet Gynaecol . 1993;  100 1076-1081
    PubMedGoogle Scholar
  • 3 Martyn C N, Gale C R, Sayer A A, Fall C. Growth in utero and cognitive function in adult life: follow-up study of people born between 1920 and 1943.  BMJ . 1996;  312 1393-1396
    PubMedGoogle Scholar
  • 4 Minior V K, Divon M VK. Fetal growth restriction at term: myth or reality?.  Obstet Gynecol . 1998;  92 57-60
    CrossrefPubMedGoogle Scholar
  • 5 Fox H, Elston C W. Pathology of the placenta. In: Bennington JL, ed. The Placenta in Abnormalities and Disorders of the Fetus London: WB Saunders 1978: 248-251
    Google Scholar
  • 6 Wentworth P. The incidence and significance of intervillous thrombi in the human placenta.  J Obstet Gynaecol Br Commonw . 1964;  71 894-898
    PubMedGoogle Scholar
  • 7 Naeye R L. Fetal growth. In: Naeye RL, Tafari N, eds. Risk Factors in Pregnancy and Diseases of the Fetus and Newborn Baltimore: Williams & Wilkins 1983: 19-75
    Google Scholar
  • 8 Salafia C M, Minior V K, Pezzullo J C, Popek E J, Rosenkrantz T S, Vintzileos A M. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathological features.  Am J Obstet Gynecol . 1995;  173 1049-1057
    CrossrefPubMedGoogle Scholar
  • 9 Rowland F N, Donovan M J, Picciano P T, Wilner G D, Kreutzer D L. Fibrin-mediated vascular injury.  Am J Pathol . 1984;  117 418-428
    PubMedGoogle Scholar
  • 10 Harris E N, Gharavi A E, Hughes G RV. Anti-phospholipid antibodies.  Clin Rheum Dis . 1985;  11 591-609
    PubMedGoogle Scholar
  • 11 Sheppard B L, Burk G, Bonnar J. Platelet activation in normotensive and hypertensive pregnancies complicated by intrauterine growth retardation.  Br J Obstet Gynaecol . 1994;  101 209-214
    PubMedGoogle Scholar
  • 12 Sugimura M, Su F, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Anticoagulant activity in non-immunoglobulin fraction from plasma of patients with antiphospholipid syndrome.  Semin Thromb Hemost . 1998;  24 473-477
    PubMedGoogle Scholar
  • 13 Miyazaki Y, Nomura S, Miyake T. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles.  Blood . 1996;  88 3456-3464
    PubMedGoogle Scholar
  • 14 Abdul Halim B M, Kanayama N, Maradny E E. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances.  Am J Obstet Gynecol . 1996;  174 272-277
    PubMedGoogle Scholar
  • 15 Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy.  Am J Obstet Gynecol . 1982;  142 159-167
    PubMedGoogle Scholar
  • 16 Lim K H, Zhou Y, Janatpour M. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia.  Am J Pathol . 1997;  151 1809-1818
    PubMedGoogle Scholar
  • 17 Lyall E, Greer I A. The vascular endothelium in normal pregnancy and pre-eclampsia.  Rev Reprod . 1996;  1 107-116
    PubMedGoogle Scholar
  • 18 Thiagarajan P, Tait J F. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles.  J Biol Chem . 1991;  66 24302-24307
    PubMedGoogle Scholar
  • 19 Kumar R, Béguin S, Hemker H C. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity.  Thromb Haemost . 1995;  74 962-968
    PubMedGoogle Scholar
  • 20 Kinlough-Rathbone R L, Perry D W. Prolonged expression of procoagulant activity of human platelets degranulated by thrombin.  Thromb Haemost . 1995;  74 958-961
    PubMedGoogle Scholar
  • 21 Drake T A, Morrissey J H, Edgington T S. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis.  Am J Pathol . 1989;  134 1087-1097
    PubMedGoogle Scholar
  • 22 Vogt E, Ng A K, Rote N S. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice.  Am J Obstet Gynecol . 1996;  174 700-707
    CrossrefPubMedGoogle Scholar
  • 23 Sugimura M, Kobayashi T, Shu F, Kanayama N, Terao T. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice.  Placenta . 1999;  20 555-560
    CrossrefPubMedGoogle Scholar
  • 24 Rand J H, Wu X-X, Guller S. Reduction of annexin-V (placental anticoagulant protein) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion.  Am J Obstet Gynecol . 1994;  171 1566-1572
    PubMedGoogle Scholar
  • 25 Shu F, Sugimura M, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia.  Gynecol Obstet Invest . 2000;  49 17-23
    CrossrefPubMedGoogle Scholar
  • 26 Funakoshi T, Heimark R, Hendrickson L E, MacMullen B A, Fujikawa K. Human placental anticoagulant protein: isolation and characterization.  Biochemistry . 1987;  26 5572-5578
    CrossrefPubMedGoogle Scholar
  • 27 Andree H AM, Stuart M CA, Hermens W T. Clustering of lipid-bound annexin V may explain its anticoagulant effect.  J Biol Chem . 1992;  267 17907-17912
    PubMedGoogle Scholar
  • 28 Sugimura M, Donato R, Kakkar V V, Scully M F. Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces.  Blood Coagul Fibrinolysis . 1994;  5 365-373
    PubMedGoogle Scholar
  • 29 Maki M, Shidara Y, Sato H. Placental annexin V isolation. Characterization and possible functions In: Moss SE, ed. The Annexins London: Portland Press 1992: 153-164
    Google Scholar
  • 30 Sato Y. Distribution and motion of calphobindin in the human body.  Acta Obstet Gynaecol Jpn . 1991;  43 65-72
    PubMedGoogle Scholar
  • 31 Krikun G, Lockwood C J, Wu X-X. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation.  Placenta . 1994;  15 601-612
    CrossrefPubMedGoogle Scholar
  • 32 Rand J H, Wu X-X, Andree H AM. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism.  N Engl J Med . 1997;  337 154-160
    CrossrefPubMedGoogle Scholar
  • 33 Schroit A J, Madsen J W, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes.  J Biol Chem . 1985;  260 5131-5138
    PubMedGoogle Scholar
  • 34 Utsugi T, Schroit A J, Connor J, Bucana C D, Fidler I. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes.  Cancer Res . 1991;  51 3062-3066
    PubMedGoogle Scholar
  • 35 Verhoven B, Schlegel R A, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes.  J Exp Med . 1995;  182 1597-1601
    CrossrefPubMedGoogle Scholar
  • 36 Nayar R, Lage J M. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome: a case report and review of the literature.  Hum Pathol . 1996;  27 201-206
    CrossrefPubMedGoogle Scholar
  • 37 Nishihira J. Reevaluation of the biological functions of macrophage migration inhibitory factor (MIF) within and beyond the immune system.  Recent Res Dev Immunol . 1999;  1 95-111
    PubMedGoogle Scholar
  • 38 Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira J. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophage in autocrine and paracrine fashion.  Immunology . 1997;  92 131-137
    CrossrefPubMedGoogle Scholar
  • 39 Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial.  Lancet . 1991;  337 1427-1431
    CrossrefPubMedGoogle Scholar
  • 40 Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ . 1997;  314 253-257
    CrossrefPubMedGoogle Scholar
      >